RobertJMotzerMD

Genitourinary Oncology, Hematologic Oncology

Attending Physician, Memorial Sloan-Kettering Cancer Center and Professor of Medicine, Cornell University-Weill Medical College

Request Appointment

Overview of Dr. Motzer

Dr. Robert Motzer is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from University of Michigan Medical School and has been in practice 36 years. Dr. Motzer accepts several types of health insurance, listed below. He is one of 464 doctors at Memorial Sloan Kettering Cancer Center and one of 88 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
MSK Sidney Kimmel Center for Prostate and Urologic Cancers
353 East 68th Street
New York, NY 10021
Book by Phone+1(424) 336-9659
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1984 - 1987
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1981 - 1984
University of Michigan Medical SchoolClass of 1981

Certifications & Licensure

FL State Medical License 2022 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 1983 - 2024
MI State Medical License 1987 - 1991
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2003-2014
America's Top Doctors Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
New York Magazine: Top Doctors Castle Connolly, 2002-2008
Join now to see all

Clinical Trials

Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin Start of enrollment: 1994 Jan 01
Completed
Phase 1, Phase 2
Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors Start of enrollment: 1994 Sep 01
Completed
Phase 3
Interferon Alfa in Treating Patients With Advanced Kidney Cancer Start of enrollment: 1998 May 01
Completed
Phase 1, Phase 2
Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2000 Jan 01
Completed
Phase 2
Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin Start of enrollment: 2000 Feb 01
Completed
Phase 2
ZD 1839 in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2001 Jan 01
Completed
Phase 2
Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment Start of enrollment: 2000 Dec 01
Completed
Phase 1
PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2002 Apr 01
Completed
Phase 2
Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2002 Apr 01
Completed
Phase 1
Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors Start of enrollment: 2004 Apr 01
Terminated
Phase 3
Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250 Start of enrollment: 2005 Jul 06
Completed
Phase 1
A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients Start of enrollment: 2006 Mar 01
Completed
Phase 1
Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment Start of enrollment: 2007 Mar 01
Completed
Phase 2
Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer Start of enrollment: 2007 Mar 01
Completed
Phase 2
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma Start of enrollment: 2007 Mar 01
Completed
Phase 2
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors Start of enrollment: 2007 Mar 01
Completed
Phase 2
A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma Start of enrollment: 2009 Dec 01
Completed
Phase 3
An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). Start of enrollment: 2010 Mar 01
Completed
Phase 3
Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies Start of enrollment: 2010 Aug 01
Completed
Phase 1
Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) Start of enrollment: 2011 Jul 01
Completed
Phase 2
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) Start of enrollment: 2011 Oct 01
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Adjuvant Immunotherapy for Kidney Cancer - A New Strategy with New Challenges.
Martin H Voss, Robert J Motzer> ;The New England Journal of Medicine. 2024 Apr 18
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
Lucia Carril-Ajuria, Pernelle Lavaud, Cecile Dalban, Sylvie Negrier, Gwénaëlle Gravis, Robert J Motzer, Christine Chevreau, Nizar M Tannir, Stéphane Oudard, David F Mc...> ;European Journal of Cancer. 2024 Apr 8
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase ...
Robert J Motzer, Toni K Choueiri, Thomas Hutson, Sun Young Rha, Javier Puente, Aly-Khan A Lalani, Eric Winquist, Masatoshi Eto, Naveen S Basappa, Nizar M Tannir, Ulka ...> ;European Urology. 2024 Apr 5
Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes.
Renée Maria Saliby, Chris Labaki, Tejas R Jammihal, Wanling Xie, Maxine Sun, Valisha Shah, Eddy Saad, M Harry Kane, Soki Kashima, Katherine Sadak, Talal El Zarif, Deep...> ;Cancer Cell. 2024 Apr 4
1 citations
Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation.
Elkrief, A., Waters, N., Smith, N., Dai, A., Slingerland, J., Aleynick, N., Febles, B., Gogia, P., Socci, N., Lumish, M., Giardina, P., Chaft, J., Eng, J., Motzer, R.,...> ;Cancer Immunology Research. 2024 Mar 4
Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma.
Donahue, A., Powles, T., Haanen, J., Larkin, J., Mu, X., Pu, J., Teresi, R., di Pietro, A., Robbins, P., Choueiri, T., Braun, D., Rini, B., Motzer, R.> ;Cancer Discovery. 2024 Mar 1
1 citations
PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients.
Thomas Denize, Opeyemi A Jegede, Sayed Matar, Nourhan El Ahmar, Destiny J West, Emily Walton, Aseman Sheshdeh Bagheri, Varunika Savla, Yasmin Nabil Laimon, Saurabh Gup...> ;Clinical Cancer Research. 2024 Feb 16
1 citations
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
Robert J Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Hilary Bagshaw, Michael Baine, Kathryn Beckermann, Maria I Carlo, Toni K Choueiri, Brian A Costello, Ithaar ...> ;Journal of the National Comprehensive Cancer Network. 2024 Feb 1
The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214.
Cella, D., Hamilton, M., Blum, S., Ivanescu, C., Karu, K., Ejzykowicz, F., Choueiri, T., Motzer, R.> ;The Oncologist. 2024 Jan 27
1 citations
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase...
Robert J Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E Hutson, Boris Alekseev, Sun Young Rha, Jaime Merchan, Jeffrey C Goh, Aly-Khan A...> ;Journal of Clinical Oncology. 2024 Apr 10
1 citations
Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Po...
Marc-Oliver Grimm, Mototsugu Oya, Toni K Choueiri, Manuela Schmidinger, David I Quinn, Gwenaelle Gravis-Mescam, Elena Verzoni, Alfonsus J M Van den Eertwegh, Alessandr...> ;European Urology. 2024 Jan 1
Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinoma.
Matulewicz, R. S., Stephen W Reese, Lennert Eismann, Charlie White, Juan Arroyave Villada, Sari Khaleel, Irina Ostrovnaya, Katiana Vazquez-Rivera, Maria I Carlo, Darre...> ;Urologic Oncology. 2024 Feb 1
A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer.
Ritesh R Kotecha, Sahil D Doshi, Andrea Knezevic, Joshua Chaim, Yingbei Chen, Rachel Jacobi, Mark Zucker, Ed Reznik, Deaglan McHugh, Neil J Shah, Emily Feld, David H A...> ;European Urology Oncology. 2023 Nov 7
Genomic ancestry in kidney cancer: Correlations with clinical and molecular features.
Kotecha, R., Knezevic, A., Arora, K., Bandlamudi, C., Kuo, F., Carlo, M., Fitzgerald, K., Feldman, D., Shah, N., Reznik, E., Hakimi, A., Carrot-Zhang, J., Mandelker, D...> ;Cancer. 2024 Mar 1
Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors.
Samuel A Funt, Andrea Knezevic, Kaamilah Wilson, Maria Bromberg, Amy Budnick, Kerri L O'Connor, Deaglan J McHugh, Erik Larsen, Dean F Bajorin, Robert J Motzer, Emily S...> ;Cancer. 2023 Dec 15
2 citations
Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab.
Neil J Shah, Sneha D Sura, Reshma Shinde, Junxin Shi, Puneet Singhal, Rodolfo F Perini, Robert J Motzer> ;Urologic Oncology. 2023 Nov 1
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized...
Robert J Motzer, Paul Russo, Viktor Grünwald, Yoshihiko Tomita, Bogdan Zurawski, Omi Parikh, Sebastiano Buti, Philippe Barthélémy, Jeffrey C Goh, Dingwei Ye, Alejo Lin...> ;Targeted Oncology. 2023 Sep 1
1 citations
Localised non-metastatic sarcomatoid renal cell carcinoma: a 31-year externally verified study.
Kyle A Blum, Andrew W Silagy, Andrea Knezevic, Stanley Weng, Alan Wang, Roy Mano, Julian Marcon, Renzo G DiNatale, Alejandro Sanchez, Satish Tickoo, Sounak Gupta, Robe...> ;BJU International. 2024 Feb 1
2 citations
Patient-reported Outcome Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic Literature Review.
Robert J Motzer, Pratik P Rane, Todd L Saretsky, Deepshikha Pawar, Allison Martin Nguyen, Joseph Burgents, Rishabh Pandey, Katja Rudell, Murali Sundaram> ;European Urology. 2023 Oct 1
Reply by Authors.
Stephen W Reese, Sari Khaleel, Andrew Silagy, Amy Xie, Lennert Eismann, Katiana Vazquez-Rivera, Sujata Patil, Jonathan Coleman, Robert Motzer, Ritesh R Kotecha, Paul R...> ;The Journal of Urology. 2023 Aug 1
5 citations
Immunometabolic coevolution defines unique microenvironmental niches in ccRCC.
Cerise Tang, Amy X Xie, Eric Minwei Liu, Fengshen Kuo, Minsoo Kim, Renzo G DiNatale, Mahdi Golkaram, Ying-Bei Chen, Sounak Gupta, Robert J Motzer, Paul Russo, Jonathan...> ;Cell Metabolism. 2023 Aug 8
1 citations
Prognostic Factors for Survival in Patients Undergoing Surveillance After Cytoreductive Nephrectomy.
Stephen W Reese, Sari Khaleel, Andrew Silagy, Amy Xie, Lennert Eismann, Katiana Vazquez-Rivera, Sujata Patil, Jonathan Coleman, Robert Motzer, Ritesh R Kotecha, Paul R...> ;The Journal of Urology. 2023 Aug 1
1 citations
Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab.
Robert Motzer, Saby George, Jaime R Merchan, Thomas E Hutson, Xun Song, Rodolfo F Perini, Ran Xie, Urmi Bapat, Javier Puente> ;The Oncologist. 2023 Jun 2
28 citations
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, ran...
Toni K Choueiri, Masatoshi Eto, Robert Motzer, Ugo De Giorgi, Tomas Buchler, Naveen S Basappa, María José Méndez-Vidal, Sergei Tjulandin, Se Hoon Park, Bohuslav Melich...> ;The Lancet. Oncology. 2023 Mar 1
10 citations
Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era.
Neil J Shah, Sneha D Sura, Reshma Shinde, Junxin Shi, Puneet K Singhal, Nicholas J Robert, Nicholas J Vogelzang, Rodolfo F Perini, Robert J Motzer> ;European Urology Open Science. 2023 Mar 1
Join now to see all

Journal Articles

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer, Thomas E Hutson, Jaime R Merchan, Corina E Dutcus, Rodolfo F Perini, Toni K Choueiri, The New England Journal of Medicine
Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...
Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Safety, Therapy Management, and Patient-Reported Outcomes in the S-TRAC Trial
Robert Motzer, MD, Annals of Oncology
Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Carcinoma
Michael B Atkins, Thomas Hutson, Mario Sznol, Toni K Choueiri, Sumanta K Pal, Richard W Joseph, John Hainsworth, W Kimryn Rathmell, David F McDermott, Robert J Motzer,..., Nature
Checkpoint Inhibitors and Other Novel Immunotherapies for Advanced Renal Cell Carcinoma
Martin H Voss, Robert J Motzer, Nature
Join now to see all

Lectures

Trial Results Establish Clinical Benefit of RAD001 in Advanced Renal Cell Carcinoma
2008 Annual Meeting, Chicago, Illinois, USA
Trial Results Establish Clinical Benefit of RAD001 in Advanced Renal Cell Carcinoma
American Society of Clinical Oncology, 2008 Annual Meeting, Chicago, Illinois, USA

Press Mentions

MSK Research Highlights, February 23, 2023February 23rd, 2023
Adjuvant Nivolumab + Ipilimumab Lacks Efficacy for Localized RCCSeptember 15th, 2022
Three Adjuvant Immunotherapy Trials Flop in Renal Cell CarcinomaSeptember 12th, 2022
Join now to see all

Grant Support

Molecular Basis Of Renal Cell Carcinoma Response To Su11428National Cancer Institute2007–2011
Clinical Trials And Mentoring In Oncology ResearchNational Cancer Institute1999–2003

Hospital Affiliations

Memorial Sloan Kettering Cancer CenterNew York, New York
Memorial Hospital for Cancer and allied DiseasesBasking Ridge, New Jersey

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
Great West PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment